Overview of alemtuzumab therapy for the treatment of T-cell lymphomas

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 789-795

  Zinzani, Pier Luigi ^a   Corradini, Paolo ^b   Gallamini, Andrea ^c   Grossi, Alberto ^d   Lazzarino, Mario ^e   Marchetti, Monia ^f   Martelli, Maurizio ^g   Rossi, Giuseppe ^h   Vitolo, Umberto ⁱ  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c S CROCE E CARLE HOSPITAL   (Italy)

^d MISERICORDIA E DOLCE HOSPITAL   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f CARDINAL MASSAIA HOSPITAL   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h Spedali Civili ^*  (Italy)

ⁱ MOLINETTE HOSPITAL   (Italy)

Author keywords

Alemtuzumab; cutaneous T cell lymphomas; peripheral T cell lymphomas

Indexed keywords

ALEMTUZUMAB; CD52 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; VINCRISTINE;

ANTIGEN EXPRESSION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CUTANEOUS T CELL LYMPHOMA; CYTOMEGALOVIRUS; DRUG EFFICACY; DRUG TOLERABILITY; HEPATITIS B VIRUS; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PERIPHERAL T CELL LYMPHOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; LYMPHOMA, T-CELL;

EID: 84859984909     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.629701     Document Type: Review

References (51)

1. Hale G, Xia MQ, Tighe HP, et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990;35:118-127. (Pubitemid 20152978)
2. Xia MQ, Hale G, Lifely MR, et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-Anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993;293:633-640. (Pubitemid 23244542)
3. Bindon CI, Hale G, Waldmann H. Importance of antigen specifi city for complement-mediated lysis by monoclonal antibodies. Eur J Immunol 1988;18:1507-1514. (Pubitemid 18269332)
4. Osterborg A, Fo a R, Bezares RF, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009;23:1980-1988.
5. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998;22:185-191. (Pubitemid 28185349)
6. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic signifi cance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998;92:76-82.
7. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103:2920-2924. (Pubitemid 38451660)
8. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101:4267-4272. (Pubitemid 36857787)
9. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as fi rst-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007;110: 2316-2323. (Pubitemid 47523150)
10. Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score. J Clin Oncol 2006;24:2472-2479. (Pubitemid 46630624)
11. Rodig SJ, Abramson JS, Pinkus GS, et al. Heterogeneous CD52 expression among hematologic neoplasms: Implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006;12:7174-7179. (Pubitemid 44974519)
12. Chang ST, Lu CL, Chuang SS. CD52 expression in non-mycotic Tand NK/T-cell lymphomas. Leuk Lymphoma 2007;48:117-121.
13. Piccaluga PP, Agostinelli C, Righi S, et al. Expression of CD52 in peripheral T-cell lymphoma. Haematologica 2007;92:566-567. (Pubitemid 350144307)
14. Jiang L, Yuan CM, Hubacheck J, et al. Variable CD52 expression in mature T cell and NK cell malignancies: Implications for alemtuzumab therapy. Br J Haematol 2009;145:173-179.
15. Geissinger E, Bonzheim I, Roth S, et al. CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specifi c T-cell receptor antibodies. Leuk Lymphoma 2009;50:1010-1016.
16. Zinzani PL, Alinari L, Tani M, et al. Preliminary observation of a phase II study of reduced-dose alemtuzumab in patients with pretreated T-cell lymphoma. Haematologica 2005;90:702-703. (Pubitemid 40780898)
17. Kim JG, Sohn SK, Chae YS, et al. Alemtuzumab plus CHOP as frontline chemotherapy for patients with peripheral T-cell lymphomas: A phase II study. Cancer Chemother Pharmacol 2007;60:129-134. (Pubitemid 46643727)
18. Binder C, Ziepert M, Loeffl er M, et al. Final analysis of phase II study of CHOP/CHOEP-14 followed by consolidation with alemtuzumab in untreated aggressive T-cell lymphomas (DSHNHL 2003-1). Blood 2007;110(Suppl. 1): Abstract 3431.
19. Intragumtonchai T, Bunworasate U, Nakorn TN, et al. Alemtuzumab in combination with CHOP and ESHAP as fi rst-line treatment in peripheral T-cell lymphoma. Blood 2006;108(Suppl. 1): Abstract 4740.
20. Janik JE, Dunleavy K, Pittaluga S, et al. A pilot trial of Campath-1H and dose-Adjusted EPOCH in CD52-expressing aggressive T-cell malignancies. Blood 2005;106(Suppl. 1): Abstract 3348.
21. Kim SJ, Kim K, Kim BS, et al. Alemtuzumab and DHAP (A-DHAP) is eff ective for relapsed peripheral T-cell lymphoma, unspecifi ed: Interim results of a phase II prospective study. Ann Oncol 2009;20:390-392.
22. Kuan JW, Lau NS, Chang KM, et al. Experience in using HyperCVAD combined with alemtuzumab in treating peripheral T-cell and T/NK cell neoplasms. Blood 2008;112(Suppl. 1): Abstract 5013.
23. Ravandi F, Aribi A, O'Brien S, et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 2009;27:5425-5430.
24. Sharma K, Janik JE, O'Mahony D, et al. Alemtuzumab (Camapth-1H) in patients with HTLV1-Asociated adult T-cell leukemia/lymphoma. Blood 2008;112(Suppl. 1); Abstract 2010.
25. Weidmann E, Hess G, Chow KU, et al. A phase II study of alemtuzumab, fl udarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk Lymphoma 2010;51:447-455.
26. Kluin-Nelemans HC, Coenen JL, Boers JE, et al. EBV-positive immunodefi ciency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood 2008;112:1039-1041.
27. Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphomas consensus recommendations for the management of cutaneous B-Cell lymphomas. Blood 2008;112:1600-1609.
28. Whittaker SJ, Marsden JR, Spittle M, et al. British Association of Dermatologists; UK Cutaneous Lymphoma Group. Joint British Association of Dermatologists and UK Cutaneous Lymphoma Group Guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003;149:1095-1107. (Pubitemid 38058085)
29. Willemze R, Dreyling M. Primary cutaneous lymphomas: ESMO clinical recommendations for diagnosis, treatment, and follow-up. Ann Oncol 2010;21(Suppl. 5):v177-v180.
30. National Comprehensive Cancer Network Guidelines 2009.
31. Alinari L, Geskin L, Grady T, et al. Subcutaneous alemtuzumab for Sezary syndrome in the very elderly. Leuk Res 2008;32:1299-1303.
32. Kennedy GA, Seymour JF, Wolf M, et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haemtol 2003;71:250-256. (Pubitemid 37174695)
33. Bernengo MG, Quaglino P, Comessatti A, et al. Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: Clinical and immunologic fi ndings in 14 patients. Haematologica 2007;92:784-794. (Pubitemid 350155304)
34. Beltran-Garate B, Gomez H, Lopez JL, et al. Alemtuzumab in patients with advanced mycosis fungoides and Sezary syndrome. Blood 2007;110(Suppl. 1): Abstract 3425.
35. Fisher DC, Tawa M, Walsh M, et al. Low-dose alemtuzumab is uniquely eff ective in refractory leukemic cutaneous T cell lymphoma (L-CTCL). Blood 2009;114(Suppl. 1): Abstract 3748.
36. Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 2004;104:65-68.
37. Querfeld C, Mehta N, Rosen ST, et al. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: A single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma 2009;50:1969-1976.
38. Rupoli S, Goteri G, Picardi P, et al. Alemtuzumab in combination with interferon or gemcitabine in aggressive and advanced cutaneous T-cell lymphomas: Report of preliminary results. Blood 2008;112(Suppl.1): Abstract 5000.
39. Lundin J, Kimby E, Bjo r kholm M, et al. A phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as fi rst-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-773. (Pubitemid 34832599)
40. Karlsson C, Lundin J, Kimby E, et al. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. Br J Haematol 2009;144:78-85.
41. Hale G, Rebello P, Brettman LR, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004;104:948-955. (Pubitemid 39043667)
42. Gibbs SD, Westerman DA, McCormack C, et al. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Br J Haematol 2005;130:87-91. (Pubitemid 40979137)
43. O'Brien S, Ravandi F, Riehl T, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumabbased therapy. Blood 2008;111:1816-1819. (Pubitemid 351451487)
44. O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 2006;7:125-130. (Pubitemid 44596594)
45. Osterborg A, Foa R, Bezares RF, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009;11:1980-1988.
46. Sohani AR, Ferry JA, Chang PS, et al. Epstein-Barr virus-positive diff use large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia. J Clin Oncol 2010;28:e69-e72.
47. Th ursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006;132:3-12. (Pubitemid 43381565)
48. Martin SI, Marty FM, Fiumara K, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006;43:16-24. (Pubitemid 43939071)
49. Lundin J, Kennedy B, Dearden C, et al. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/S e zary syndrome. Blood 2005;105:4148-4149. (Pubitemid 40656170)
50. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. J Clin Oncol 2011;29:1182-1189.
51. Coiffi er B, Pro B, Prince HM, et al. Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy. Blood 2010;116(Suppl. 1): Abstract 114.